RNS Number:7749T
VASTox plc
27 March 2007


                                   VASTox plc
                          ("VASTox" or "the Company")

               PAYMENT OF NON-EXECUTIVE DIRECTORS' FEES IN SHARES


Oxford, UK, 27 March 2007 - VASTox plc (AIM: VOX) today announces that the
Non-executive Directors of the Company have agreed to receive no less than 25
per cent. of their cumulative director fees in VASTox shares ("Non-executive
Share Ownership Scheme"). The Non-executive Share Ownership Scheme takes effect
from 1 February 2007 and the percentage of fees taken as shares will be agreed
annually in advance by individual Non-executive directors.

The shares will be purchased from the market on behalf of the Non-executive
Directors by the Company's broker.  The purchase of shares will begin on 28
March 2007 and then on a quarterly basis on 30 April, 31 July, 31 October and 31
January.

The current holdings and share purchase commitment for the year ending 31
January 2008 are shown below.


Non-executive Director         Shareholding at 26       Percentage of    % of fees to be taken as
                                   March 2007          Ordinary Shares   shares in the year ending
                                                                                31 Jan 2008
Barry Price                             -                                           25%
Stephen Davies                      6,208,748               16.7%                    -
David Norwood                           -                                          100%
Sir Brian Richards                      -                                           50%
Colin Wall                           74,000                 0.15%                    -



                                    - ends -


For more information, please contact:


VASTox
Steven Lee, PhD, Chief Executive Officer                       Tel: +44 (0)1235 443951
Darren Millington, Chief Financial Officer

Citigate Dewe Rogerson
Mark Swallow / David Dible / Valerie Auffray                   Tel: +44 (0)207 638 9571


About VASTox plc

VASTox is a leading UK biotechnology company that discovers and develops
proprietary new drugs. The Company's internal drug development programmes are
underpinned by its advanced chemistry and drug screening (chemical genomics)
technology platforms, which it also provides on a collaborative or
fee-for-service basis to the pharmaceutical industry.

VASTox has a broad range of drug discovery programmes in the clinical,
pre-clinical and discovery stages of development, which target serious diseases
with a high unmet medical need. These therapeutic areas include neuro-disorders
(neurodegenerative and neuromuscular), anti-infectives, ophthalmic diseases,
oncology and regenerative medicines.

VASTox's in-house drug development capabilities combine world-class expertise in
both medicinal and carbohydrate chemistry with high-volume, high-content
screening using its proprietary zebrafish and fruitfly technologies (chemical
genomics). These whole organism screens have the potential to dramatically
decrease the time and cost of drug discovery and development by delivering data
that are highly predictive of the efficacy and toxicity of potential drug
compounds in humans.

The company listed on the AIM market of the London Stock Exchange in October
2004 - symbol: VOX

Further information about the company is available at www.vastox.com.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
RDSIIFEAVSIDFID
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Vox Valor Capital Charts.
Vox Valor Capital (LSE:VOX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Vox Valor Capital Charts.